Clear Search

Showing 1 result for “Citera G Peterfy CG Pope JE Winthrop K L Bergman M Grimm SE Nash P Shamail GMH Strand V Uchio A”.

January 2022

Cytokine Signalling Forum: Single slide summaries – January 2022


Upadacitinib as monotherapy or in combination with background MTX was effective in inhibiting the progression of structural joint damage through Week 48 in MTX-naïve and MTX‐inadequate responder patients with RA.Recently approved in many countries for the treatment of RA, upadacitinib has been shown to significantly reduce the progression of structural joint damage in two Phase 3 studies (SELECT-EARLY and SELECT-COMPARE). In this analysis, Peterfy, et al. evaluated the progression of structural ...